Lien Lybaert, interim CEO of Persomed

Cancer treatment has come a long way in recent decades, but a significant portion of patients remain unresponsive to traditional treatments and novel immunotherapies. Personalised cell therapy may be a new option in treating these patients.

Persomed is developing such a platform targeting cancer patients and the company is led by Dr Lien Lybaert. She discusses her journey to the CEO role, Persomed's work on the platform, and her challenges raising funds for their first clinical trial.